The Valley Desk

NCT03003676 · Interventional trial

A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

Overall registry status Completed

Phase 1

Conditions Advanced or Unresectable Melanoma Progressing After PD1 Blockade

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov